
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is a promising investment due to their strong financial performance, conservative approach, and potential for growth through new products and partnerships. While their stock is currently undervalued, the launch of TruVu and promising pipeline for Alzheimer's diagnostics could drive significant growth and recapture market share. However, there are potential risks to consider with any investment, such as changing reimbursement and competition in the radiopharmaceutical industry.
Bears say
Lantheus Holdings is facing headwinds in its Radiopharmaceutical Oncology segment, with a decline in net ASP and volume despite the growing PSMA PET market. The delayed CEO successor announcement could signal potential disruptions in the company's long-term growth plans, and while there are some promising opportunities in the pipeline, there is uncertainty around their potential contribution to revenue. In addition, the change in price target to $115 based on a 20x multiple of the 2027 earnings per share highlights the company's current struggles to maintain its competitive edge.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares